Wim Pluymers is currently Medical Head Cell and Gene therapies Western European cluster a.i. and Medical Lead Cell and Gene therapies for Belgium-Luxembourg at Novartis Oncology. He was involved from the start in the clinical development of CART therapy, subsequent pre-launch preparation and set-up of commercialization of this innovative therapy in Belgium.
Wim holds a PhD in the field of HIV-1 antiviral research from the University of Leuven in Belgium. He transitioned to medical affairs in the pharma industry after his academic career, which spanned both the university of Leuven and the University of Southern California in Los Angeles.